Biologic

WASHINGTON — Physicians have a variety of safe and effective biologic choices for treating children with asthma, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Induction and maintenance treatment with infliximab was more efficacious than vedolizumab in patients with Crohn’s disease, while efficacy was similar between the two therapies in patients with ulcerative colitis, according to data.

According to published results, patients who underwent arthroscopic rotator cuff repair with vs. without bone marrow stimulation had similar rates of healing, postoperative clinical outcome scores and range of motion.

WASHINGTON — Allergic status did not impact annualized asthma exacerbation rate reductions seen with mepolizumab, benralizumab and tezepelumab in patients with moderate to severe, uncontrolled asthma, according to study results.

Patients with plaque psoriasis that have lower baseline blood monocyte counts may respond to secukinumab therapy earlier than patients with higher counts, according to a study.

In this Healio video exclusive, Michael V. Chiorean, MD, explains that physicians can safely and “with confidence” switch patients with inflammatory bowel disease from an originator biologic to a biosimilar at any point during treatment.

Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.

Abrocitinib downregulated genes associated with inflammation, epidermal hyperplasia, and T helper 2 and T helper 22 responses in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.

The introduction of biologics as a therapeutic option for Crohn’s disease had “only a slight impact” on eventual surgery occurrence, although it may delay the first intestinal resection compared with conventional therapy, data showed.

Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.